CelLBxHealth plc (AIM:CLBX)

Market Cap	14.49M -24.9%
Revenue (ttm)	1.15M -56.1%
Net Income	-12.94M
EPS	-0.02
Shares Out	1.14B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	933,097
Open	1.281
Previous Close	1.275
Day's Range	1.250 - 1.347
52-Week Range	0.850 - 7.995
Beta	0.43
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 7, 2026

About CelLBxHealth

CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis; and Parsortix PR1 system captures and harvests circulating tumour cells from blood. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with analytic...

• Industry: Medical - Diagnostics & Research
• Sector: Healthcare
• Founded: 1994
• Employees: 119
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: CLBX

Financial Performance

In 2025, CelLBxHealth's revenue was 1.35 million, a decrease of -52.80% compared to the previous year's 2.86 million. Losses were -19.51 million, 37.1% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 27, 2026

Data Sources Report a data error